159 related articles for article (PubMed ID: 36142729)
21.
Tan J; Liu R; Zhu G; Umbricht CB; Xing M
Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648
[TBL] [Abstract][Full Text] [Related]
22. Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review.
Stögbauer L; Stummer W; Senner V; Brokinkel B
Neurosurg Rev; 2020 Jun; 43(3):903-910. PubMed ID: 30788677
[TBL] [Abstract][Full Text] [Related]
23. Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma.
Ahmad F; Dixit D; Sharma V; Kumar A; Joshi SD; Sarkar C; Sen E
Cell Death Dis; 2016 May; 7(5):e2213. PubMed ID: 27148686
[TBL] [Abstract][Full Text] [Related]
24. Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells.
Braunstein I; Cohen-Barak O; Shachaf C; Ravel Y; Yalon-Hacohen M; Mills GB; Tzukerman M; Skorecki KL
Cancer Res; 2001 Jul; 61(14):5529-36. PubMed ID: 11454703
[TBL] [Abstract][Full Text] [Related]
25. TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation.
Vallarelli AF; Rachakonda PS; André J; Heidenreich B; Riffaud L; Bensussan A; Kumar R; Dumaz N
Oncotarget; 2016 Aug; 7(33):53127-53136. PubMed ID: 27449293
[TBL] [Abstract][Full Text] [Related]
26. CPSF4 activates telomerase reverse transcriptase and predicts poor prognosis in human lung adenocarcinomas.
Chen W; Qin L; Wang S; Li M; Shi D; Tian Y; Wang J; Fu L; Li Z; Guo W; Yu W; Yuan Y; Kang T; Huang W; Deng W
Mol Oncol; 2014 May; 8(3):704-16. PubMed ID: 24618080
[TBL] [Abstract][Full Text] [Related]
27. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
28. Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway.
Maida Y; Kyo S; Kanaya T; Wang Z; Yatabe N; Tanaka M; Nakamura M; Ohmichi M; Gotoh N; Murakami S; Inoue M
Oncogene; 2002 Jun; 21(26):4071-9. PubMed ID: 12037663
[TBL] [Abstract][Full Text] [Related]
29. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
Landa I; Ganly I; Chan TA; Mitsutake N; Matsuse M; Ibrahimpasic T; Ghossein RA; Fagin JA
J Clin Endocrinol Metab; 2013 Sep; 98(9):E1562-6. PubMed ID: 23833040
[TBL] [Abstract][Full Text] [Related]
30. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.
Borah S; Xi L; Zaug AJ; Powell NM; Dancik GM; Cohen SB; Costello JC; Theodorescu D; Cech TR
Science; 2015 Feb; 347(6225):1006-10. PubMed ID: 25722414
[TBL] [Abstract][Full Text] [Related]
31. Highly recurrent TERT promoter mutations in human melanoma.
Huang FW; Hodis E; Xu MJ; Kryukov GV; Chin L; Garraway LA
Science; 2013 Feb; 339(6122):957-9. PubMed ID: 23348506
[TBL] [Abstract][Full Text] [Related]
32. An enhanced hTERT promoter-driven CRISPR/Cas9 system selectively inhibits the progression of bladder cancer cells.
Huang X; Zhuang C; Zhuang C; Xiong T; Li Y; Gui Y
Mol Biosyst; 2017 Aug; 13(9):1713-1721. PubMed ID: 28702647
[TBL] [Abstract][Full Text] [Related]
33. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM
Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586
[TBL] [Abstract][Full Text] [Related]
34. Telomerase reverse transcriptase promoter regulation during myogenic differentiation of human RD rhabdomyosarcoma cells.
Ma H; Urquidi V; Wong J; Kleeman J; Goodison S
Mol Cancer Res; 2003 Aug; 1(10):739-46. PubMed ID: 12939399
[TBL] [Abstract][Full Text] [Related]
35. Role of menin in the regulation of telomerase activity in normal and cancer cells.
Hashimoto M; Kyo S; Hua X; Tahara H; Nakajima M; Takakura M; Sakaguchi J; Maida Y; Nakamura M; Ikoma T; Mizumoto Y; Inoue M
Int J Oncol; 2008 Aug; 33(2):333-40. PubMed ID: 18636154
[TBL] [Abstract][Full Text] [Related]
36. High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins.
Zheng X; Zhuge J; Bezerra SM; Faraj SF; Munari E; Fallon JT; Yang XJ; Argani P; Netto GJ; Zhong M
J Hematol Oncol; 2014 Jul; 7():47. PubMed ID: 25042800
[TBL] [Abstract][Full Text] [Related]
37. Upstream stimulatory factor (USF) as a transcriptional suppressor of human telomerase reverse transcriptase (hTERT) in oral cancer cells.
Chang JT; Yang HT; Wang TC; Cheng AJ
Mol Carcinog; 2005 Nov; 44(3):183-92. PubMed ID: 16010690
[TBL] [Abstract][Full Text] [Related]
38. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas.
Li Y; Cheng HS; Chng WJ; Tergaonkar V
Proc Natl Acad Sci U S A; 2016 Dec; 113(50):14402-14407. PubMed ID: 27911794
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells.
Xu D; Wang Q; Gruber A; Björkholm M; Chen Z; Zaid A; Selivanova G; Peterson C; Wiman KG; Pisa P
Oncogene; 2000 Oct; 19(45):5123-33. PubMed ID: 11064449
[TBL] [Abstract][Full Text] [Related]
40. Activating Telomerase
Zvereva M; Pisarev E; Hosen I; Kisil O; Matskeplishvili S; Kubareva E; Kamalov D; Tivtikyan A; Manel A; Vian E; Kamalov A; Ecke T; Calvez-Kelm FL
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
